Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas.

Andrade DV, Warnes C, Young E, Katzelnick LC, Balmaseda A, de Silva AM, Baric RS, Harris E.

Sci Rep. 2019 Nov 7;9(1):16258. doi: 10.1038/s41598-019-52511-z.

2.

Effects of infection history on dengue virus infection and pathogenicity.

Tsang TK, Ghebremariam SL, Gresh L, Gordon A, Halloran ME, Katzelnick LC, Rojas DP, Kuan G, Balmaseda A, Sugimoto J, Harris E, Longini IM Jr, Yang Y.

Nat Commun. 2019 Mar 18;10(1):1246. doi: 10.1038/s41467-019-09193-y.

3.

Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika.

Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC, Montoya M, Michlmayr D, Kuan G, Balmaseda A, Coloma J, de Silva AM, Harris E.

Nat Commun. 2019 Feb 26;10(1):938. doi: 10.1038/s41467-019-08845-3.

4.

Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua.

Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, Chowell G, Lopez B, Elizondo D, Coloma J, Burger-Calderon R, Kuan G, Balmaseda A, Harris E.

PLoS Med. 2019 Jan 22;16(1):e1002726. doi: 10.1371/journal.pmed.1002726. eCollection 2019 Jan.

5.

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus.

Katzelnick LC, Coello Escoto A, McElvany BD, Chávez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT.

PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862. doi: 10.1371/journal.pntd.0006862. eCollection 2018 Oct.

6.

Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua.

Katzelnick LC, Ben-Shachar R, Mercado JC, Rodriguez-Barraquer I, Elizondo D, Arguello S, Nuñez A, Ojeda S, Sanchez N, Lopez Mercado B, Gresh L, Burger-Calderon R, Kuan G, Gordon A, Balmaseda A, Harris E.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10762-10767. doi: 10.1073/pnas.1809253115. Epub 2018 Sep 28.

7.

Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.

Wang W, Chen Q, Ford-Siltz LA, Katzelnick LC, Parra GI, Song HS, Vassell R, Weiss CD.

Clin Infect Dis. 2019 May 30;68(12):2067-2078. doi: 10.1093/cid/ciy818.

PMID:
30256912
8.

Reconstruction of antibody dynamics and infection histories to evaluate dengue risk.

Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, Thaisomboonsuk B, Nisalak A, Weg A, Ellison D, Macareo L, Yoon IK, Jarman R, Thomas S, Rothman AL, Endy T, Cauchemez S.

Nature. 2018 May;557(7707):719-723. doi: 10.1038/s41586-018-0157-4. Epub 2018 May 23.

9.

Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.

Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, Schildhauer S, Supasa P, Vasanawathana S, Malasit P, Mongkolsapaya J, de Silva AD, Tissera H, Balmaseda A, Screaton G, de Silva AM, Harris E.

J Infect Dis. 2018 Jul 13;218(4):536-545. doi: 10.1093/infdis/jiy164.

10.

The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Katzelnick LC, Harris E.

Curr Opin Virol. 2018 Apr;29:51-61. doi: 10.1016/j.coviro.2018.03.004. Epub 2018 Mar 26. Review.

11.

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J.

Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7.

12.

Antibody-dependent enhancement of severe dengue disease in humans.

Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E.

Science. 2017 Nov 17;358(6365):929-932. doi: 10.1126/science.aan6836. Epub 2017 Nov 2.

13.

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.

Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E.

MBio. 2017 Sep 19;8(5). pii: e01205-17. doi: 10.1128/mBio.01205-17.

14.

Immune correlates of protection for dengue: State of the art and research agenda.

Katzelnick LC, Harris E; Participants in the Summit on Dengue Immune Correlates of Protection.

Vaccine. 2017 Aug 24;35(36):4659-4669. doi: 10.1016/j.vaccine.2017.07.045. Epub 2017 Jul 28.

15.

Dengue: knowledge gaps, unmet needs, and research priorities.

Katzelnick LC, Coloma J, Harris E.

Lancet Infect Dis. 2017 Mar;17(3):e88-e100. doi: 10.1016/S1473-3099(16)30473-X. Epub 2017 Feb 7. Review.

16.

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. Epub 2016 Jan 4.

17.

Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization.

Wang C, Katzelnick LC, Montoya M, Hue KD, Simmons CP, Harris E.

J Infect Dis. 2016 Mar 15;213(6):975-84. doi: 10.1093/infdis/jiv536. Epub 2015 Nov 17.

18.

Dengue viruses cluster antigenically but not as discrete serotypes.

Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, Russell CA, Thu HM, Pierson TC, Buchy P, Aaskov JG, Muñoz-Jordán JL, Vasilakis N, Gibbons RV, Tesh RB, Osterhaus AD, Fouchier RA, Durbin A, Simmons CP, Holmes EC, Harris E, Whitehead SS, Smith DJ.

Science. 2015 Sep 18;349(6254):1338-43. doi: 10.1126/science.aac5017.

19.

Antibody landscapes after influenza virus infection or vaccination.

Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NMH, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WEP, Le QM, Nguyen TH, Wertheim HFL, Hurt AC, Osterhaus ADME, Barr IG, Fouchier RAM, Horby PW, Smith DJ.

Science. 2014 Nov 21;346(6212):996-1000. doi: 10.1126/science.1256427.

20.

Quantifying the fitness advantage of polymerase substitutions in Influenza A/H7N9 viruses during adaptation to humans.

Fonville JM, Burke DF, Lewis NS, Katzelnick LC, Russell CA.

PLoS One. 2013 Sep 27;8(9):e76047. doi: 10.1371/journal.pone.0076047. eCollection 2013.

Supplemental Content

Loading ...
Support Center